NL
DE
17 January 2020
The BeNeFIT (Belgium-Netherlands Funding of International Trials) program, in which ZonMw and the Belgian KCE have joined forces, has honored the first two grant applications. One of these is a study into the dose reduction of biologics in psoriasis, carried out by Elke de Jong and Juul van den Reek and UZ Gent, Jo Lambert and Lynda Grine. Reduction of new generation biologics in psoriasis. This awarded project concerns research into dose reduction of new generation biologics in psoriasis. Biologics are very effective agents for the treatment of psoriasis. Previous research has shown that the dose of TNFα-blocking biologics can be reduced in some patients. For the new generation of biologics, IL17 and IL23 inhibitors, it is not yet known whether dose reduction of these agents is possible. The new agents have different mechanisms and safety profiles in comparison with TNFα blockers and are increasingly prescribed. It is therefore important to investigate the possibilities for dose reduction of these new biologics in a timely manner.
ZonMw and KCE granted 1.6 millon euros to perform this large multinational study in 17 hospitals in Belgium and the Netherlands.
The BeNeFIT (Belgium-Netherlands Funding of International Trials) program, in which ZonMw and the Belgian KCE have joined forces, has honored the first two grant applications. One of these is a study into the dose reduction of biologics in psoriasis, carried out by Elke de Jong and Juul van den Reek and UZ Gent, Jo Lambert and Lynda Grine. Reduction of new generation biologics in psoriasis. This awarded project concerns research into dose reduction of new generation biologics in psoriasis. Biologics are very effective agents for the treatment of psoriasis. Previous research has shown that the dose of TNFα-blocking biologics can be reduced in some patients. For the new generation of biologics, IL17 and IL23 inhibitors, it is not yet known whether dose reduction of these agents is possible. The new agents have different mechanisms and safety profiles in comparison with TNFα blockers and are increasingly prescribed. It is therefore important to investigate the possibilities for dose reduction of these new biologics in a timely manner.
ZonMw and KCE granted 1.6 millon euros to perform this large multinational study in 17 hospitals in Belgium and the Netherlands.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
RIHS Awards 2022 Call open for nominations
4 October 2022RIHS researchers are invited to propose candidates for the RIHS PhD Award, the Societal Impact Award, the Science Award, the Supervisor of the year Award, and the RIHS Patient Involvement Award. Deadline for submission is 8 November 2022.
read more
Grants for heart and kidney research Two awards to Radboudumc in Open Competition ENW-XS
21 July 2022Two researchers from the Radboudumc receive a grant from the NWO within the Open Competition of the Exact and Natural Sciences. They are Thijs Eijsvogels, who studies the heart, and Pieter Leermakers, who studies the kidneys.
read more
More than five million euros for research to improve palliative care Jeroen Hasselaar will lead research project with Horizon grant
15 June 2022 Jeroen Hasselaar will lead a large international research project. With a 5.3 million euro grant from the EU's Horizon program, he and his team want to improve palliative care for cancer patients, together with partners from nine European countries. read more
Large NWA ORC grant awarded for national skin research: Next Generation ImmunoDermatology
23 March 2022 Research for better treatment methods for chronic skin diseases. read more
ZonMw grants to study optimal use of COVID-19 vaccines in patients with impaired immune systems
3 February 2021 How do people with reduced immunity, especially kidney patients, react to a COVID-19 vaccination? And how can patients with peripheral arterial disease be helped by DNA testing? Our researchers received grants from ZonMw to make these studies possible. read more
